Inside Takeda’s Plasma-Derived Therapy Ecosystem
Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...
CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update
Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.
Business Insider3y
The $24 billion plasma industry may be putting donors at risk
According to analysts at Fortune Business Insights, two-thirds of these centers are owned by one of three companies: CSL Plasma, Grifols, and BioLife. Even before the pandemic hit, global demand ...
Morningstar11d
Demand for CSL’s Plasma Products Persists as Supply Improves
CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint ...
Nature3y
A red blood cell disease meets a company with a plasma protein heritage
which is now known as global biotechnology leader CSL Behring; US plasma collector Nabi, which helped to form the world’s premier plasma collection company in CSL Plasma; the Novartis influenza ...
Investing11d
CSL lifts HY profit as plasma sales jump, offsets flu vaccine weakness
CSL) reported a rise in half-year net profit, driven primarily by robust performance in its blood plasma division. The company's CSL Behring unit, which focuses on plasma-derived therapies ...
Morningstar11d
CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business — Update
Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business. Australia-based CSL, which runs a network of ...